4Moving Biotech has successfully closed a €12 million financing round to advance its lead disease-modifying osteoarthritis drug candidate for knee osteoarthritis. The clinical-stage biotech, a spin-off of 4P-Pharma focused on first-in-class treatments that could alter the course of osteoarthritis, completed the funding through a structured process supported by private investors and family offices.

The combination of equity and loans extends the company’s financial runway to reach a critical proof-of-concept milestone in its Phase 2a programme while reinforcing its strategy for long-term value creation. This funding follows prior public support including a France 2030 grant and coincides with the transatlantic expansion of its INFLAM-MOTION study into the United States. With approximately €30 million raised to date, leadership says the company is now well positioned to generate robust clinical data and prepare for interactions with regulatory agencies. The investment underlines growing confidence in 4Moving Biotech’s innovative approach to addressing a major unmet need for millions of patients worldwide living with knee osteoarthritis, a condition with no approved disease-modifying therapies.